| 标题 |
 A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial |
| 网址 | |
| DOI | |
| 其它 |
期刊：Journal of Clinical Oncology 作者：Kevin Kalinsky; Melissa Kate Accordino; Codruta Chiuzan; Prabhjot Singh Mundi; Meghna S. Trivedi; et al 出版日期：2022 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)
wwww
东方元语
cdercder
Nole
xing_xing
Dean
Maestro_S
学术文献互助
馆长
aajhajkahna
无奈的梦凡
Criminology34
Kao
arniu2008
初景
aaaa
Juvenilesy
七听
Car66614
sagitar
皖公网安备34019202002308
